Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)

This Notice of Funding Opportunity (NOFO) is a limited competition that invites U01 competing continuation applications for the continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), a clinical consortium composed of one Data Coordinating Center (DCC) and up to ten Clinical Centers (CC) to continue a prospective longitudinal observational study of the incidence of diabetes that occurs during or after an acute pancreatitis (AP) episode, with an emphasis on type 1 diabetes (T1D) [the Diabetes Related to Acute Pancreatitis and its Mechanisms (DREAM) study] (NCT05197920). The study has been designed to gain insight into the incidence, clinical evolution, etiology, type, and pathophysiology of T1D and other forms of diabetes that occur during, or after one or more episodes of AP. The DREAM study is expected to be near its target enrollment of patients who have experienced AP during the current award segment, and so this NOFO will support applications largely intended for completion of recruitment and longitudinal observation of the assembled cohort, including monitoring for the incidence of T1D and other forms of diabetes, and the identification of immune, genetic, environmental, behavioral and demographic risk factors and biomarkers. This competition is limited to Clinical Centers that are currently participating in the consortium and funded by grants awarded through RFA-DK-19-022.

A competing continuation application for the DCC will be submitted in response to a separate NOFO, RFA-DK-25-018: Single Source for the Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional).

Key Dates

Open Date: 10/21/2024

Letter of Intent Due Date: October 21, 2024

Application Due Date: November 19, 2024